The liver-brain neurodegeneration axis encompasses the bidirectional communication pathways through which the liver influences brain function and neurodegeneration, and through which CNS pathology may reciprocally affect hepatic metabolism. This axis operates through multiple overlapping mechanisms: the accumulation of ammonia and other neurotoxic solutes in liver failure, the release of mitochondrial DNA (mtDNA) and other damage-associated molecular patterns (DAMPs) from damaged hepatocytes into systemic circulation, the loss of liver-derived neurotrophic factors, the bidirectional link between non-alcoholic fatty liver disease (NAFLD) and neurodegenerative diseases, and the liver's critical role in processing gut-derived metabolites before they reach the brain. The liver's central position in metabolism, detoxification, and systemic immune regulation makes it a crucial determinant of brain health and a major contributor to neurodegenerative processes when its function is compromised.
The liver-brain neurodegeneration axis encompasses the bidirectional communication pathways through which the liver influences brain function and neurodegeneration, and through which CNS pathology may reciprocally affect hepatic metabolism. This axis operates through multiple overlapping mechanisms: the accumulation of ammonia and other neurotoxic solutes in liver failure, the release of mitochondrial DNA (mtDNA) and other damage-associated molecular patterns (DAMPs) from damaged hepatocytes into systemic circulation, the loss of liver-derived neurotrophic factors, the bidirectional link between non-alcoholic fatty liver disease (NAFLD) and neurodegenerative diseases, and the liver's critical role in processing gut-derived metabolites before they reach the brain. The liver's central position in metabolism, detoxification, and systemic immune regulation makes it a crucial determinant of brain health and a major contributor to neurodegenerative processes when its function is compromised.
The clinical significance of this axis is substantial: patients with chronic liver disease show elevated rates of cognitive impairment and have an increased incidence of both Alzheimer's disease (AD) and Parkinson's disease (PD). Conversely, neurodegenerative diseases are associated with hepatic dysfunction through multiple pathways. The liver-brain axis provides mechanistic explanations for these clinical associations and identifies therapeutic opportunities for protecting the brain by improving liver health, reducing toxic metabolite burden, and modulating liver-derived signaling to the CNS.
Hepatic encephalopathy (HE) is the syndrome of neuropsychiatric abnormalities that occurs as a consequence of liver failure, representing the most severe manifestation of the liver-brain axis[@butterworth2002]. HE ranges from minimal cognitive impairment detectable only by neuropsychometric testing to overt confusion, asterixis (flapping tremor), coma, and death. The pathophysiology of HE is complex and multifactorial, but ammonia plays a central role. The healthy liver converts ammonia (a product of protein catabolism and gut bacterial metabolism) to urea through the urea cycle, maintaining circulating ammonia at non-toxic levels (typically 15-45 μmol/L). When liver function is compromised, ammonia accumulates in blood and crosses the blood-brain barrier, exerting direct neurotoxic effects[@arao2020].
Ammonia neurotoxicity manifests through several mechanisms. In astrocytes—the cells most sensitive to ammonia in the brain—ammonia disrupts glutamine synthetase activity, leading to accumulation of glutamine in astrocytes, which exerts osmotic effects causing astrocyte swelling and cerebral edema. Ammonia also impairs astrocyte function by disrupting the glutamate transporter (GLT-1), leading to impaired glutamate uptake and excitotoxic effects. Mitochondrial dysfunction in neurons is another consequence of ammonia exposure, as ammonia impairs the electron transport chain and promotes oxidative stress. Furthermore, ammonia alters the permeability of the blood-brain barrier (BBB), allowing additional neurotoxic substances to reach the brain[@bernardi2019].
While HE is classically associated with cirrhosis and acute liver failure, subclinical ammonia elevation and chronic low-grade hepatic dysfunction may contribute to neurodegeneration in patients without overt liver disease[@schrader2020]. Studies have demonstrated that even modest elevations in blood ammonia—below the threshold for clinical HE—can impair cognitive function, alter neurotransmission, and promote neuroinflammation. This is particularly relevant for patients with chronic kidney disease (who have elevated ammonia due to impaired urea excretion), those with gut dysbiosis (who have increased ammonia production from bacterial urease), and elderly individuals with age-related decline in hepatic function.
The mechanisms through which ammonia may contribute to neurodegeneration include direct promotion of protein aggregation. In vitro studies have demonstrated that ammonia exposure increases [alpha-synuclein](/proteins/alpha-synuclein) (αSyn) expression and aggregation in neurons, and ammonia levels correlate with markers of neuroinflammation in human studies. Ammonia also potentiates the effects of other neurotoxins, creating a "double hit" that accelerates neurodegeneration in susceptible individuals. The concept of subclinical hepatic dysfunction contributing to cognitive decline has gained traction, with studies linking elevated ammonia to impaired executive function and reduced processing speed even in patients without diagnosed liver disease.
Treatment of HE focuses on reducing ammonia production and enhancing ammonia clearance[@bernardi2019]. Lactulose, a non-absorbable disaccharide, is the first-line therapy: it is metabolized by colonic bacteria to lactic and acetic acid, lowering colonic pH, which converts ammonia (NH3) to the non-absorbable ammonium (NH4+), effectively trapping ammonia in the gut lumen for excretion. Lactulose also has a cathartic effect that reduces bacterial overgrowth and ammonia production. Rifaximin, a non-absorbable antibiotic, reduces ammonia-producing gut bacteria and is used as adjunctive therapy to lactulose. L-ornithine L-aspartate (LOLA) provides substrate for the urea cycle and glutamine synthesis, directly reducing ammonia levels. Protein restriction, once standard care for HE, is now recognized as counterproductive given the risk of sarcopenia and malnutrition in cirrhotic patients.
The primary mechanism of ammonia neurotoxicity involves the conversion of ammonia to glutamine in astrocytes by glutamine synthetase[@arao2020]. This reaction is normally protective, as it removes ammonia from the brain, but when ammonia levels are elevated, the excess glutamine accumulation in astrocytes causes osmotic stress, leading to cell swelling. The swelling of astrocytes disrupts their normal functions including potassium buffering, neurotransmitter clearance (particularly glutamate), and maintenance of the BBB. The resulting astrocyte dysfunction contributes to neuronal hyperexcitability, impaired neurotransmission, and cognitive impairment.
The astrocyte swelling in HE is compounded by alterations in water channel expression (aquaporin-4, AQP4), changes in cell volume regulation mechanisms, and disruption of the astrocyte-endothelial interface that maintains BBB integrity. In acute liver failure, the cerebral edema from astrocyte swelling can be fatal due to increased intracranial pressure. In chronic liver disease, the degree of astrocyte swelling is more moderate but still contributes to cognitive dysfunction through the mechanisms described above.
Ammonia impairs neuronal and astrocyte mitochondrial function through multiple mechanisms[@correa2017]. Ammonia inhibits the electron transport chain, particularly Complex I and Complex IV, reducing ATP production and increasing electron leak that generates reactive oxygen species (ROS). The resulting oxidative stress damages mitochondrial proteins, lipids, and mtDNA. Ammonia also depletes α-ketoglutarate, a critical intermediate in the TCA cycle and a substrate for several key enzymes, disrupting astrocyte energy metabolism. The combination of impaired energy production and increased oxidative stress makes neurons more vulnerable to excitotoxicity and protein aggregation.
The mitochondrial effects of ammonia are particularly relevant for dopaminergic neurons, which have high basal oxidative stress due to dopamine metabolism. Ammonia exposure compounds this vulnerability, potentially contributing to the selective loss of dopaminergic neurons in PD. Studies in animal models have shown that ammonia exposure potentiates the toxicity of known PD-inducing toxins such as MPTP and 6-OHDA, suggesting that even subclinical ammonia elevation could accelerate PD pathology in susceptible individuals.
Ammonia disrupts multiple neurotransmitter systems in the brain. Glutamate, the primary excitatory neurotransmitter, is affected through altered synthesis (glutamine synthetase diverts glutamate to glutamine), reduced release, and impaired reuptake. The resulting hyperexcitability contributes to seizure susceptibility in HE. GABAergic transmission is also altered: ammonia increases GABA synthesis (through glutamine → GABA pathway) but impairs GABA receptor function, leading to mixed effects on inhibitory neurotransmission that contribute to the cognitive dysfunction and asterixis characteristic of HE.
Monoamine neurotransmitters are affected as well. Dopamine turnover is altered in HE, and reduced dopaminergic function contributes to the motor and cognitive symptoms of liver disease. Serotonin levels are elevated in some studies of HE, consistent with altered tryptophan metabolism. These neurotransmitter alterations contribute to the characteristic neuropsychiatric symptoms of HE and may interact with the primary pathological processes of AD and PD.
Mitochondrial DNA (mtDNA) is released from damaged hepatocytes into the circulation in liver disease, acting as a damage-associated molecular pattern (DAMP) that triggers systemic inflammation and reaches the brain to promote neuroinflammation[@garcia2022]. The mechanisms of mtDNA release include mitochondrial permeability transition pore (mPTP) opening in damaged hepatocytes, mitochondrial outer membrane permeabilization (MOMP), and rupture of mitochondria during necrotic cell death. In liver diseases characterized by hepatocyte death—including viral hepatitis, alcoholic liver disease, NAFLD/NASH, and cirrhosis—mtDNA release into the cytoplasm, then into the systemic circulation, creates a state of chronic systemic inflammation.
Once in circulation, mtDNA acts through multiple pattern recognition receptors. Cytosolic mtDNA activates the cGAS-STING pathway, triggering type I interferon responses. Extracellular mtDNA activates TLR9 on immune cells, promoting inflammatory cytokine production. The chronic elevation of circulating mtDNA in liver disease creates a persistent inflammatory signal that can reach the brain through multiple routes: directly crossing the BBB, activating the vagal afferent system, or triggering hepatic inflammation that communicates to the brain via blood-borne signals.
The effects of hepatic mtDNA release on the brain include activation of microglial cells, promotion of neuroinflammation, and potentially direct effects on neurons[@garcia2022]. Microglia express TLR9 and other pattern recognition receptors that respond to mtDNA, activating NF-κB and IRF signaling pathways that promote pro-inflammatory cytokine production. The resulting microglial activation contributes to chronic neuroinflammation, a hallmark of virtually all neurodegenerative diseases. In animal models, circulating mtDNA from liver-injured donors is sufficient to activate microglia and promote behavioral changes consistent with cognitive impairment.
Additionally, mtDNA and mitochondrial DAMPs may directly promote protein aggregation. The inflammatory milieu created by mtDNA-driven inflammation promotes oxidative stress and cellular dysfunction, creating conditions favorable for αSyn and Aβ aggregation. In PD models, hepatic mtDNA release accelerates αSyn pathology in the substantia nigra, and in AD models, it promotes amyloid pathology. The concept of the "inflamed liver" as a source of circulating neurotoxic signals that accelerate neurodegeneration is increasingly supported by experimental evidence.
The release of hepatic mtDNA is particularly relevant in the context of NAFLD (non-alcoholic fatty liver disease) and its progressive form NASH (non-alcoholic steatohepatitis)[@chen2020]. NAFLD affects approximately 25% of the global population and is closely linked to metabolic syndrome, obesity, and type 2 diabetes—conditions that also increase neurodegenerative disease risk. NASH is characterized by hepatocyte injury, inflammation, and progressively, fibrosis. The injured hepatocytes in NASH release mtDNA and other DAMPs into circulation, driving the systemic inflammation that connects NAFLD/NASH to neurodegeneration.
Multiple epidemiological studies have demonstrated significant associations between NAFLD/NASH and neurodegenerative diseases[@romach2019]. A large Korean cohort study found that NAFLD was associated with a 20-30% increased risk of PD and a 10-20% increased risk of AD after adjustment for metabolic risk factors. Studies using the UK Biobank and other large databases have confirmed these associations, with some suggesting dose-response relationships between NAFLD severity and neurodegenerative disease risk. The association persists after adjustment for obesity, diabetes, and cardiovascular risk factors, suggesting that NAFLD contributes to neurodegeneration through mechanisms beyond shared metabolic risk factors.
The mechanisms linking NAFLD/NASH to neurodegeneration are multifactorial[@gallucci2021]. First, NAFLD/NASH generates a state of chronic systemic inflammation characterized by elevated TNF-α, IL-6, and IL-1β, which reach the brain and activate microglia. Second, NAFLD is associated with altered lipid metabolism and elevated circulating lipids that affect brain function, including ceramides and free fatty acids that are directly neurotoxic. Third, NAFLD reduces the liver's capacity to clear toxins and produce neurotrophic factors, compromising the liver's protective functions for the brain. Fourth, NAFLD promotes insulin resistance, which independently increases neurodegenerative disease risk through impaired brain glucose metabolism.
NAFLD also alters the production and clearance of liver-derived factors relevant to neurodegeneration. The synthesis of neurotrophic factors such as [brain-derived neurotrophic factor](/proteins/bdnf-protein) (BDNF) and hepatocyte growth factor (HGF) is impaired in NAFLD. Paraoxonase-1 (PON1), an antioxidant enzyme with neuroprotective properties synthesized by the liver, is reduced in NAFLD. The reduction of these protective factors removes a brake on neurodegeneration. Additionally, NAFLD increases the production of fetuin-A and other liver-secreted proteins that may have complex effects on brain inflammation and protein aggregation.
Genetic studies have revealed overlap between susceptibility to NAFLD and neurodegenerative diseases, supporting shared underlying pathways[@cagnoli2018]. The PNPLA3 gene variant (I148M), the strongest known genetic determinant of NAFLD/NASH, has been associated with altered lipid metabolism and insulin resistance that are relevant to neurodegeneration. Variants in other NAFLD-associated genes may also influence neurodegenerative disease risk through effects on lipid metabolism, inflammation, and mitochondrial function. The TM6SF2 variant, which increases NAFLD risk, has been linked to altered circulating lipids and possibly to neurodegenerative disease risk.
NAFLD is associated with cognitive dysfunction even in the absence of cirrhosis, suggesting that hepatic lipid accumulation itself affects brain function[@gallucci2021]. Studies have documented impaired performance on cognitive testing, particularly executive function and processing speed, in patients with NAFLD compared to matched controls without NAFLD. Brain imaging studies have shown reduced brain volume and altered white matter integrity in NAFLD patients. These findings suggest that the liver-brain axis in NAFLD involves effects on cognition that may represent early neurodegeneration or a pre-degenerative state.
Serum albumin, synthesized exclusively by the liver, is the most abundant plasma protein and serves multiple functions relevant to neurodegeneration[@seethapathy2019]. Albumin carries and delivers fatty acids, hormones, and drugs to the brain through receptor-mediated transcytosis. Albumin-bound bilirubin has been identified as a neurotrophic factor that promotes neuronal survival and neurite outgrowth. The albumin-to-fetuin ratio in cerebrospinal fluid (CSF) is used as a marker of blood-brain barrier integrity, with elevated ratios indicating BBB dysfunction. In liver disease, reduced albumin synthesis compromises these protective functions, contributing to neurodegeneration.
The paraoxonase (PON) family of enzymes—PON1, PON2, and PON3—are synthesized in the liver and associate with high-density lipoprotein (HDL) particles[@gao2021]. PON1 is particularly important for neuroprotection through its antioxidant functions: it prevents LDL oxidation, hydrolyzes lipid peroxides, and protects against oxidative stress in the brain. PON1 activity is reduced in AD and PD patients, and lower PON1 activity correlates with more severe disease. In NAFLD/NASH, PON1 activity is further reduced due to decreased hepatic synthesis and increased consumption by antioxidant processes, creating a double deficit in neuroprotection.
Fetuin-A (AHSG, alpha-2-HS-glycoprotein) is a liver-secreted plasma protein that crosses the BBB and exerts effects on the brain[@deanne2019]. Fetuin-A acts as a ligand for TGF-β receptors and modulates neuroinflammation through effects on microglial activation. Studies have shown that fetuin-A levels decline with age and are further reduced in liver disease. The age-related decline in fetuin-A parallels the increased risk of neurodegeneration with aging, and experimental studies have shown that fetuin-A supplementation has neuroprotective effects. Reduced fetuin-A in liver disease removes another protective mechanism through which the liver supports brain health.
Direct ammonia reduction through lactulose, rifaximin, and LOLA remains the cornerstone of treating hepatic encephalopathy. For subclinical ammonia elevation contributing to neurodegeneration, these same strategies may have neuroprotective benefits, though this has not been rigorously tested in neurodegeneration prevention trials. Protein restriction (now considered counterproductive in cirrhosis) may nonetheless be beneficial in non-cirrhotic individuals with elevated ammonia and early cognitive decline. Probiotics that reduce ammonia-producing gut bacteria are another approach.
Lifestyle modification—weight loss, exercise, and dietary change—is the primary treatment for NAFLD/NASH and may have secondary benefits for neurodegeneration by reducing systemic inflammation, improving insulin sensitivity, and restoring liver-derived neurotrophic factor production. Pharmacological treatments for NASH, including GLP-1 receptor agonists (which reduce body weight and improve insulin sensitivity) and FXR agonists (which improve hepatic lipid metabolism), are under active investigation and may provide dual benefits for liver health and neurodegeneration prevention.
Approaches to enhance liver-derived neurotrophic factors include:
Modulating the gut microbiome to reduce ammonia and toxic metabolite production benefits the liver-brain axis from the gut side. Dietary interventions—particularly Mediterranean-style diets that reduce hepatic fat accumulation and shift gut microbiome composition—are beneficial for both NAFLD and neurodegeneration. Probiotics, prebiotics, and synbiotics that reduce ammonia production and restore gut barrier function offer a gut-first approach to protecting the liver and brain simultaneously.
The liver-brain neurodegeneration axis intersects with multiple other mechanisms:
The liver-brain neurodegeneration axis represents a fundamental pathway through which hepatic function influences brain health and disease:
Understanding this axis positions the liver as a critical therapeutic target for neurodegenerative disease prevention and treatment, linking metabolic liver disease management to brain health outcomes.
Related Hypotheses:
The following diagram shows the key molecular relationships involving Liver-Brain Neurodegeneration Axis discovered through SciDEX knowledge graph analysis: